UNIVERSIDAD DE BARCELONA
FACULTAD DE MEDICINA

DESARROLLO DE UNA VACUNA PREVENTIVA CONTRA EL VIH, BASADA EN BCG RECOMBINANTE

TESIS DOCTORAL: ELIAS B. PEZZAT SAID
21 DE JUNIO DE 2005

VIII.BIBLIOGRAFÍA

- Aidsinfo.nih.gov/document/data/es_protocol-libPROT-ES-1483.html
- Aldovini A., Young R.A. Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines. **Nature 351, 479-82(1991)**
- Alexandroff AB. BCG immunotherapy of bladder cancer: 20 years on. **Lancet 353, 689-94(1999)**
- Altet G. M., Alcaide M.J., Jiménez F.M., et al. La vacuna BCG: la controversia continúa. **Vacunas 4; 95-101(2003)**
- Al-Zarouni M., Dale J.W. Expressión of foreign genes in Mycobacterium bovis BCG strains using different promoters reveals instability of the hsp60 promoter for expression of foreign genes in Mycobacterium bovis BCG strains. **Tuberculosis 82(6), 283-291 (2002)**
- Arnold G.F., Velasco P.K., Wrin T., et al. Neutralization of diverse HIV-1 primary isolates elicited by gp41 ELDKWA-displaying human rhinovirus selected from combinatorial libraries. (abstrac 96) **AIDS Vaccine Lausanne 2004**
- Autran B.1, Carcelain G., Li T.S. et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. **Science 277:112-16 (1997).**
- Autran B.2, Buve A., Largarde E., Kahindo M., Chege J., Rutenberg N., et al. Study Group on the heterogeneity of HIV Epidemics in African Cities. Male circumcision and HIV infection in four cities in sub-Saharian Africa. **AIDS 2001; Suppl 4: S31-40**.
- Autran B.3, Debré P., Walker B., et al. Therapeutic vaccines against HIV need international partnerships. **Nat Rep Immuno. 3, (6):503-8, (2003).**
- Barouch D.H., Kinsman J., Glowczwskie J., et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from CTL.**J Virol 77(13) :7367-75 2003**
- Barouch D., Lemcker A., Havenga M. et al. Immunogenicity of heterologous prime-boost vaccine regimens involving adenovirus serotypes 11 and 35. (Abstract 14) **AIDS Vaccine Lausanne 2004**
- Barton G.M, Medzhitov R., Toll-like receptor signalling pathways. **Science 6; 300(5625):1524-58, (2003)**
- Betts m., West s., Nason m. et al. The functional hierarchy of the HIV-1 specific CD8+T-cell response is dominated by MIP 1b. International aids vaccine conference, Lausanne 2004
- Biet, F., Kremer,L., Wolowczuck, I. Delacre M., et al. Immune response induced bye recombinant Mycobacterium bovis producing the cholera toxin B subunit. **Infec immun 71 (5):2933-7 (2003.)**
- Blankson J.N., Persaud D., Siliciano R.F. The challenge of viral reservoirs in HIV-1 infection. **Annu Rev Med. 53:557-63 2002**
- Bloom B.R., Fine P.E. The BCG experience: implications for future vaccines against tuberculosis. Tuberculosis: Pathogenesis, Protection and Control, ASM Press 531-557(1994).
- Boaz M., Keystone Symposium: Updates on trials, new candidates and immune basis of protection. **IAVI Report 2003**

- Bogdan C. The function of type I interferons in antimicrobial immunity.**Curr. Opin. Immunol. 12 419-24(2000)**
- Bojak A., Deml L., Wagner R. The past, present and future of HIV-vaccine development: a critical view. **Drug Discov Today 1;7(1):36-46, (2002)**
- Bollinger R.C., Brookmayer R.S., Mehendale S.M., et al. Risk factors and clinical presentation of acute primary HIV infection in India. **JAMA 278: 2085-9, (1997).**
- Boniotto M., Crovella S., Pirulli D., Scarlatti G., Spano A., Vatta L., et al., Polymorphisms in the MBL2 promoter correlated with risk of HIV-1 vertical transmission and AIDS progression, **Genes Immun. 1 346-48(2000)**
- Botarelli P., Houlden B.A., Haigwood N.L., et al. N-glycosilation of HIV-gp120 may constrain recognition by T lymphocytes, **Immunol 1;147(9): 3128-32,(1991).**
- Burton D. R.1, Antibodies, Viruses and Vaccines. **Nature 2: 706-713, (2002).**
- Burton D.R.2, Parren P.W. Vaccines and the induction of functional antibodies: time to look beyond the molecules of natural infection, **Nat Med 6(2): 123-5m, (2000).**
- Burton D.R., Desrosiers R.C., Doms R.W., et al. A sound rationale needed for phase III HIV-1 Trials. **Science 303:316, (2004).**
- Burton D.R. Challenges involved in eliciting neutralizing antibodies to HIV. **11th CROI, 108 (2004).**
- Cao H., Kaleebu P., Hom D., et al. HIV network for prevention trials immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers. **J. Infect Disease 187(6):887-95, (2003).**
- Carcelain G., Tubiana R., Samri A., et al. Transient movilitazation of human immunodefiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1. **J. Virology 75:234-1, (2001).**
- Carr A. Samaras K., Thorisdottir et al. Diagnosis prediction and natural course of HIV-1 protease inhibitor-associated lipodystrophy, hyperlipidemia and diabetes mellitus : a cohort study. **Lancet 353: 2093-99 (1999)**
- Carrington M., Nelson G.W., Martin M.P. et al. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage, **Science 12;283(5408):1748-52,(1999).**
- Casimiro D.R., Tang A., Perry H.C., et al. Vaccine-induced immune responses in rodents and nonhuman primates by use of humanized human immunodeficiency virus type 1 pol gen. **J.Virol 76:185-94, (2002).**
- CDC. Public health service guidelines for postexposure prophylaxis. **MMWR. 50 (RR11): 1-42 (2001)**
- Chantratita W., Sukeepaisarncharoen W., Chandeying V., et al. Delayed progression to AIDS in volunteers treated with long-therm HIV-1

immunogen (REMUNE) therapy in Thailand. **HIV Med. 5(5):317-25, (2004).**

- Chun T.W., Stuyver L., Mizell S.B. et al. Presence o fan inducible HIV-1 latent reservoir during highly active antiretroviral therapy, **Proc Natl Acad Sci USA 25; 94(24): 13193-7, (1997).**
- Clark s.J., Saag M.S., Decker W.D., et al. High titters of cytophatic virus in plasma of patients with symptomatic primary HIV-1 infection. **N.Engl J Med 324:954-60, (1991).**
- Clerici M., Barassi C., Devito C. et al. Serum IgA of HIV-exposed uninfected individuals inhibit HIV through recognition of a region within the (alpha)-helix of gp41. **AIDS 16(13):1731-41, (2002).**
- Cocchi F.1, DeVico A.L., Garzino-Demo A., Arya S.K., Gallo R.C., Lusso P. Identification of RANTES, MIP-1alpha, and MIP-1beta as the major HIV-suppressive factors produced by CD8 T cells, **Science 270:1811-15, (1995).**
- Cocchi F.2, DeVico A.L, Yarchoan R. et al. Higher macrophage inflammatory protein MIP-alpha and MIP-beta levels from CD8+ T cells are associated with asymptomatic HIV-1 infection, **Proc Natl Acad sci USA 5;97(25): 13812-7, (2000).**
- Cohen J., Escape artist par excellence. **Science ; 299: 1505-07 (2003)**
- Colditz G.A., Brewer T.F., Berkey C.S., et al. Efficacy of BCG vaccine in the prevention of tuberculosis. **JAMA 271:698-702, (1994).**
- Connell ND, Medina-Acosta E, McMaster WR, Bloom BR, Russell DG. Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette-Guerin expressing the Leishmania surface proteinase gp63**. Proc Natl Acad Sci U S A 15;90(24):11473-7, (1993).**
- Cooper D.A., Gold J., Maclean P., et al. Acute AIDS retrovirus infection. Definiton of a clinical illness associated with seroconvertion. **Lancet 1: 537-40, (1985).**
- Daniel M.D., Kirchchoff F.,Csajak S.C., Sehgal P.K., Desrosiers R.C. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. **Science 18;258(5090):1880-1, (1992)**.
- DasGupta S. et al. Expression Systems for Study of Mycobacterial Gene Regulation and Development of BCG Vaccines. **Biochemical and Biophysical Reserch Comunications 246, 797-804 (1998)**
- Deeks S.G., Wrin T., Liegler et al. Virologic in HIV infected patients with detectable viremia. **N Engl J Med. 344: 472-80 (2001)**.
- Descamps D., Peytavin G., Calvez V. Et al Mechanisms of virologic failure in previously untreated HIV infected patients from a trial of induction-maintenance therapy (Trilege): **JAMA 283: 205-11 (2000).**
- Dhar N., Rao V., Tyagi A.K. skewing of Th1/Th2 responses in mice due to variation in the level of expression of an antigen in a recombinant BCG system. **Immunology Letters 88:175-84, (2003).**
- Dhar N., Rao V., Tyagi A. Recombinant BCG approach for development of vaccines: cloning and expresión of immunodominant antigens of M. tuberculosis. **FEMS Microbiol Lett 190(2):309-16 (2000)**
- DHHS (Departament of Health and Human Services and the Henry J. Kaiser Family Foundation. Guidelines for the use of antiretroviral agents

in HIV-1-infected adults and adolescents: http://www.hivatis.org. Revised April 7, (2005)

- Dietrich G., Viret J.F., Hess J. Novel vaccination strategies based on recombinant Mycobacterium bovis BCG. **Int J. Med Microbiol 292(7-8):441-51, (2003).**
- Doan LX., Li M., Chen C. et al. Virus-like particles as HIV-1 vaccines. **Rev Med Virol. (2004)**
- Donners H.The firts generation of candidate HIV-1 vaccine can induce antibodies able to neutralize primary isolates in assays with extended incubation phases. **Vaccine 8;22(1):104-11, (2003).**
- Dragic T. An overtview of the determinants of CCR5 and CXCR4 co-receptor fuction**. J. Gen Virol. Aug; 82 (Pt 8):1807-17, (2001).**
- Dye C.1, Scheele S., Doli P. et al. Global burden of tuberculosis: estimated incidence, prevalence and mortality by country. **JAMA 282: 677-86(1999)**
- Dye C. Tuberculosis 2000-2010: control, but not elimination. **Int J. Tuberc Lung Dis 4(12suppl 2):S146-52,(2000).**
- Emini E.A. A potential HIV-1 vaccine using a replication-defective adenoviral vaccine vector. In **9th Conference on Retroviruses and Opportunistic Infections: Seatle, Washintong, (2002**).
- Engelmayer J., Larsson M., Lee A., et al. Mature dentritic cells infected with canarypox virus elicit strong anti-human immunodeficiency virus CD8+ and CD4+ T- cell response from chronically infected individuals. **J. Virology 75 (5):2142-53, (2001).**
- Esparza J, et al. HIV Vaccines: A Global Perspective. **Current Molecular Medicine 3, 183-194, (2003).**
- Esparza J. An Hiv vaccine: how and when?. **Bull World Health Organ 79(12): 1133-7, (2001).**
- Ezekowitz A.B., Kuhlman M.,Groopman J.E., Bym R.A. A human serum manose-binding protein inhibits in vitro infection by the human inmunodeficiency virus. **J. Exp. Med. 169 185-96, (1989).**
- Fanales-B E., Cafaro A., Cara A et al. HIV-1 Tat-based vaccines: form basic science to clinical trials. **DNA Cell Biol. 21(9):599-610, (2002).**
- Fauci S.A. HIV and AIDS: 20 years of science. **Nature Medicine 9, 839-842, (2003).**
- Falk L.A., Goldenthal K.L., Esparza J., et al. Recombinant bacillus Calmette Guérin as a potencial vector for preventive HIV-1 vaccines. **AIDS Res Hum Retroviruses 20; 16(2):91-8, (2000).**
- Fennelly GJ, Flynn JL, ter Meulen V, Liebert UG, Bloom BR. Recombinant bacille Calmette-Guerin priming against measles. **J Infect Dis 172(3):698-705, (1995)**.
- Fernandez-Cruz E., Moreno S., Navarro J. et al. Therapeutic immunization with an inactivated Hiv-1 immunogen plus antiretroviral versus antiretroviral therapy alone in asymptomatic HIV-infected subjects. **Vaccine 22:2966-73, (2004).**
- Finzi D., Blankson J., Siliciano J.D. et al. Latent infection of CD4+ T cells provides a mechanism for lifefelong persistence of HIV-1 even in patients on effective combination therapy. **Nat Med 5:512-17,(1999).**

- Fischl M.A., Richman D.D., Grieco M.H. Efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: A double-blind, placebo-controlled trial. **N.Engl J Med 317:185-191 (1987)**
- Francis D.P., Heyward W.L., Popovic V., et al. Candidate HIV-AIDS vaccine: Lessons learned from de World's first fase III efficacy trials. **AIDS 17 (2):147-56, (2003).**
- Fuerst TR, de la Cruz VF, Bansal GP, Stover CK.Development and analysis of recombinant BCG vector systems. **AIDS Res Hum Retroviruses 8(8):1451-5, (1992).**
- Gao X., Nelson G.W., Karacki P., et al. Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDSS. **N Engl J. Med, 344: 1668-75, 2001.**
- Garber D.A., Feinberg M.B. AIDS vaccine development: the long and winding road. **AIDS Rev. 5(3):131-9 (2003)**
- García F., Plana M., Vidal C. et al. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. **AIDS. 13(11):F79-86, (1999)**.
- Garcia F., Plana M., Soriano A. Et al. The virological and immunological consequences of structured treatment interruptions in a chonic HIV-1 infection. **AIDS 15:F29-F40 (2001)**
- García F., Lejeune M., Climent N., et al.Therapeutic immunization with dentritic cells loaded with inactivated autologous HIV-1 in chronic HIV-1 infected patients: A pilot randomized trial. **J Infect Dis (In press), (2005).**
- Gascon RL., Narvaez AB., Zhang R., kahn JO., Hecht FM., Herndier BG., et al. Increased HLA-DR expression on peripheral blood monocytes in subsets of subjects with primary HIV infection is associated with elevated CD4 cell depletetion. **J. acquir Inmune Defic Syndr. 30:146-53, (2002**).
- Gatell J.M., Blanco J.L., Alcamí J. et al Documento de consenso de GESIDA sobre utilización de los estudios de resistencias en la práctica clínica: **Enferm Infecc Microbiol 19:53-60 (2001)**
- Gebo K.A., Moore R.D. Treatment of HIV infection in the older patient. **Expert Rev Anti Infect Ther. 2(5):733-43, (2004).**
- Gheorghiu M., Lagranderie M., Gicquel B. et al. Mycobacterium bovis BCG priming induces a strong potentiation of the antibody response induced by recombinant BCG expressing a foreing antigen. **Infect Immun 62(10):4287-95 (1994)**
- Goldsby R. Infection and Immunity. **Immunology Fifth edition, 389-413, (2003).**
- Goulder P.J. 2, Brander C., Tang Y, et al. Evolution and transmisión of stable CTL escape mutations in HIV infection. **Nature, 412:334-8, (2001).**
- Gray CM., Lawrence J., Schapiro JM. et al. Frequency of class I HLA-restricted anti-HIV-1 CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART). **J immunol. 162(3):1780-8, (1999).**
- Hadida F., Viellard V., Mollet L. et al. Cutting edge: RANTES regulates Fas ligand expression and killing by HIV-specific CD8 cytotoxic T cells, **J Immunol. 1;163(39):1105-9, (1999).**

- Haeseleer F. Structural instability of recombinant plasmids in mycobacteria. **Res. Microbiol. 145, 683-687 (1994)**
- Harrer E.1, Bauerle M., Ferstl B. et al. Analysis of nef-specific T-cells viral rebound and autologus viral sequences during, Structured treatment interruption after therapeutic vaccination with a MVA-BN-Nef vaccine in HIV-1-infected patients on HAART. **11th CROI poster abstracts 519, (2004).**
- Harrer E.2, Bauerle M., Ferstl B., et al. Phase 1 study with a therapeutic MVA-BN-Nef vaccine in HIV-1 infected patients on HAART. **10º Conference on retroviruses and opportunistic infection, A 60.**
- Hecht F.M., Busch M.P., Rawal B., et al. Use of laboratory test and clinical symptoms for indetification of primary HIV infection. **AIDS 16:1119-29, (2002).**
- Henrad D.R., et al. Virologic and immunologic characterizacion of symptomatic and asymptomatic primary HIV-1 infection. **J Acquir Immune Defic syndr 9:305-10, (1995).**
- Hiroishi K., Tuting T., Lotze M.T. IFN-alpha-expressing tumor cells enhance **generation** and promote survival of tumor-specific CTLs, **J. Immunol. 164 567-72, (2000).**
- Hirsch M.S., Brun-Vezinet F., Clotet B. et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1 : 2003 recommendations of an international AIDS Society-USA Panel. **Clin Infec Dis 1;37(1):113-28 (2003)**
- Ho DD.,Neumann Au., Perelson As., Zhang R., Kahn JO., Hecht FM:, Herndier BG., et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. **Nature 373:123-6, (1995**).
- Honda M, Matsuo K, Nakasone T, Okamoto Y, Yoshizaki H, Kitamura K, Sugiura W, Watanabe K, Fukushima Y, Haga S, et al. Protective immune responses induced by secretion of a chimeric soluble protein from a recombinant Mycobacterium bovis bacillus Calmette-Guerin vector candidate vaccine for human immunodeficiency virus type 1 in small animals. **Proc Natl Acad Sci U S A 7;92(23):10693-7, (1995).**
- Hu J., Gardner MB., Miller CJ. Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dentritic cells**. J. Virol, 74: 6087-95, (2000).**
- Hung C.C., Chang S.C. Impact of highly active antiretroviral therapy on incidence management of human immunodeficiency virus-related opportunistic infections. **J. Antimicrob Chemother Sept, (2004).**
- Husson RN. Gene replacement and expression of foreign DNA in mycobacteria. **J Bacteriol 172, 519-24, (1990).**
- Idemior V. HIV: scientific challenges impeding candidate vaccines, **HIV Clin Trials 4(6) 421-4, (2003).**
- Iribarren J.A., Labarga P., Rubio R. et al. Spanish GESIDA/Nacional AIDS Plan recommendations for antiretroviral therapy in HIV-infected adults **Enferm Infecc Microbiol Clin. 22(10):564-642, (2004).**
- Jacobs W.R., Tuckman M., Bloom B.R. Introduction of foreign DNA into mycobacteria using a shuttle plasmid. **Nature 327, 532-5, (1987).**

- Jeffrey T. Safrit. HIV vaccines in infants and children: Past trials, present plnas and future perspective. **Curr Molec Med 3:309-18, (2003).**
- Kameoka M., Nishino Y., Matsuo K., et al. Cytotoxic T lymphocyte response in mice induced by a recombinant BCG vaccination which produces an extracellular alpha antigen that fused with the human immunodeficiency virus type 1 envelope immunodominant domain in the V3 loop. **Vaccine 12(2):153-158 (1994).**
- Kassutto S., Rosenberg E. Primary HIV Type 1 Infection, **CID 38:1447-53, (2004).**
- Kaslow R.A., Carrington M., Apple R. et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection, **Nat Med. 2(4):405-11, (1996).**
- Kaufmann D:, Pantaleo G., Sudre P. Et al CD4-cell count in HIV-1-infected individuals remaining viremic with higly active antiretroviral therapy (HAART). Swiss HIV Cohort Study. **LANCET 351:723-24 (1998)**
- Kaul R.1, Plummer F.A., Kimani J. et al. HIV-1 specific mucosal CD8+ lymphocyte responses in the cervix of HIV-1 resistant prostitutes in Nairobi, **J Immunol. 1;164(3):1602-11, (2000).**
- Kaul R.2,Rowland-Jones S.L., Kimani J., et al. Late seroconversion in HIV-resistant Nairobi prostitutes despite preexisting HIV-specific CD8+ responses, **J Clin Invst. 107(3):341- 9, (2001).**
- Kavoussi LR. et al. Results of 6 weekly intravesical bacillus Calmette Guérin instillatios on the treatament of superficial bladder tumors. **J Urol 139:935-40, (1988).**
- Kelleher A.D., Long C., Holmes E.C. et al. Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses, **J Exp Med. 5;193(3):375-86, (2001).**
- Khan J.O.1, Walker B.D. Acute human inmunnodeficiency virus type 1 infection, **N Engl Med 339:33-9, (1998).**
- Khan J.O.2, Cherng D.W., Mayer K., et al Evaluation of HIV-1 immunogen and immunologyc monifafier, administered to patients infected with HIV having 300 to 549 X10 (6)/L CD4 cells counts: A randomized controlled trial. **JAMA 284:2193-2202, (2000).**
- Klein M. Prospects and Challenges for Prophylactic and Therapeutic HIV Vaccines**. Vaccines 21:616-619, (2003).**
- Knobel H., Codina C., Miró J.M. The recommendations of GESIDA/SEFH/PNS for improving adherence to antiretroviral treatment. AIDS Study Group of the Spanish Society of Hospital Pharmacy and the National Plan on AIDS of the Minister of Health and Consumers. **Enferm Infecc Microbiol Clin. 18 (1):27-39, (2000).**
- Knobel H., Escobar I., Polo R., Ortega L. Et al. Recomendaciones GESIDA/SEP/PNS para mejorar la adherencia al tratamiento antirretroviral. **Enferm Infecc Microbiol Clin 23(4):221-31 (2004)**
- Kong D, Kunimoto DY. Secretion of human interleukin 2 by recombinant Mycobacterium bovis BCG. Infect Immun 63(3):799-803, (1995).
- Koup R.A., Safit J.T., Cao Y. et al. Temporal association of cellular immune responses with the initial control of viremia in primary human inmmunedeficiency virus type 1 syndrome. **J.Virol 68(7):4650-5, (1994).**

- Labrijn AF. Access of antibody molecules to conserved coreceptor binding site on glycoprotein gp 120 is sterically restricted on primary HIV-1 **J Virol 77(19):10557-65, (2003).**
- Lafeuillade A., Chaffanjon P., Pellegrino P., et al. Oesophageal candidiasis in primary in HIV infection. **Eur J Med 1:126, (1992).**
- Lagranderie M 1, Murray A, Gicquel B, Leclerc C, Gheorghiu M.Oral immunization with recombinant BCG induces cellular and humoral immune responses against the foreign antigen. **Vaccines 11(13):1283-90, (1993).**
- Lagranderie M. 2, Balazuc AM, Gicquel B, Gheorghiu M.Oral immunization with recombinant Mycobacterium bovis BCG simian immunodeficiency virus nef induces local and systemic cytotoxic T-lymphocyte responses in mice. **J Virol 71(3):2303-9, (1997).**
- Lagranderie M. 3, Winter N, Balazuc AM, Gicquel B, Gheorghiu M.A Cocktail of Mycobacterium bovis BCG recombinants expressing the SIV Nef, Env, and Gag antigens induces antibody and cytotoxic responses in mice vaccinated by different mucosal routes. **AIDS Res Hum Retroviruses 20;14(18):1625-33, (1998).**
- Lalezari J., Eron J.,Carlson M. et al. Safety pharmacokinetics, ans antiretroviral activity of T-20 as single agent in heavily pretreated patients. **6th Conference Retroviruses Opportunistic Infections Chicago 1999**
- Lallemant-Le C., Lallemant M., Cheynier D. et al. BCG immunization in infants bom to to HIV-1-seropositive mothers. **AIDS 5(2):195-99 (1991).**
- Langermann S, Palaszynski SR, Burlein JE, Koenig S, Hanson MS, Briles DE, Stover CK. Protective humoral response against pneumococcal infection in mice elicited by recombinant bacille Calmette-Guerin vaccines expressing pneumococcal surface protein A. **J Exp Med 180(6):2277-86,(1994).**
- Layvreys L., Thompsom M.L., Martin H.L., et al. Primary human immunodeficiency virus type 1 infection: Clinical manifestations among women in Mombaza, Kenya. **Clin Infec Dis 30:486-90, (2002).**
- Lee C.F.1, Chang S.Y., Hsieh D.S. et al. Treatment of bladder carcinomas using recombinant BCG d vaccines and electroporative gene immunotherapy. **Cancer Gene Ther. 11(3):194-207, (2004).**
- Lee C.F.2, Chang S.Y., Hsieh D.S., Immunotherapy for bladder cancer using recombinant bacille Calmette-Guerin DNA vaccines and IL-12 DNA vaccine. **J.Urol 171(3):1343-7, (2004).**
- Lee E. The impact of phase III efficacy trials on community involcement support and awareses of HIV vaccine research: A case study of the AIDSVAX trials. **XV international AIDS conference Bangkok, Thailand, A C1429, (2004).**
- Letvin N.1 Strategies for an HIV vaccine. **J. Clin. Invest. 109, 15-20(2002)**
- Letvin N.2 Progress in the development of an HIV-1 vaccine. **Science 280:1875-79, (1998).**
- Letvin N.3, Walker B.D., Immunopathogenesis and immunotherapy in AIDS virus infections. **Nat Med. 9:861-66, (2003).**

- Leung NJ, Aldovini A, Young R, Jarvis MA, Smith JM, Meyer D, Anderson DE, Carlos MP, Gardner MB, Torres JV.The kinetics of specific immune responses in rhesus monkeys inoculated with live recombinant BCG expressing SIV Gag, Pol, Env, and Nef proteins. **Virology 268(1):94-103, (2000).**
- Levy J.A.1 The importante of innate system in controlingh HIV infection and disease, **Trends Immunol 22: 312-16, (2001).**
- Levy J.A. 2 HIV and the pathogenesis of AIDS, **American Society of Microbiology 2nd edition, (1998)**
- Levy J.A., The search for the CD8+ cell anti-VIH factor (**CAF**). **Trends Immunol. (review) 24(12):628-32, (2003)**
- Letvin N. and Walker B. Immunopathogenesis and immunotherapy in AIDS virus infections. **Nature, 9:861-866, (2003).**
- Lim EM, Lagranderie M, Le Grand R, Rauzier J, Gheorghiu M, Gicquel B, Winter N. Recombinant Mycobacterium bovis BCG producing the N-terminal half of SIVmac251 Env antigen induces neutralizing antibodies and cytotoxic T lymphocyte responses in mice and guinea pigs. **AIDS Res Hum Retroviruses 10;13(18):1573-81, (1997)**
- Liu C., Carrington M., Kaslow R.A., et al. Association of polymorphisms in human leukocyte antigen processing genes with resistence to human immunodeficiency virus type 1 infection. **J infect Dis. 187:1404-10, (2003).**
- Liu R., Paxton W.A., Choe S., Ceradini D., Martin S.R., Horuk, et al. Homozygotus defect in HIV coreceptor accounts for resistance for some multiply-exposed individuals to HIV-1 infection, **Cell 86:366-77, (1996).**
- Lopez C., Firzgerald P.A., Siegal F.P. Severe acquired immune deficiency syndrome in male homosexual diminished capacity to make interferon-alpha in vitro associated with severe opportunistic infections, **J. Infect. Dis 148:962-66, (1983).**
- Lorin C., Mollet C., Combredet C. et al. Measles vaccine as a potential vector for AIDS vaccination. **AIDS Vaccine Lausanne (abstrac 13)**, (**2004).**
- Lu Wei.1, Arraes L., Ferreira W. et al. Therapeutic dentritic-cell vaccine for chronic HIV-1 infection. **Nat. Medicine, advance on line 1-7, (2004).**
- Lu Wei.2, Wu X., Lu Y., et al. Therapeutic dentritic cell vaccine for simian AIDS. **Nature Medicine 9(1):27-32, (2003).**
- Lucas S., Nelson A. Pathogenesis of tuberculosis in human immunodeficiency virus-infected people. In Bloom B., editor **Tuberculosis. Pathogenesis, Protection and Control. Washington, DC: 503-13 (2002)**
- Lusso P. HIV and chemokines: Implications for therapy and vaccine. **Vaccine 20:1964-67, (2002).**
- Mackewicz C.E.1, Barker E., Levy J.A. Role of beta-chemokines in supresión HIV replication, **Science 274 1393-95, (1996).**
- Mackewicz C.E.2, Yang L.C., Lifson J.D., Levy J.A. Non-citolytic CD8 T cell anti-HIV responses in primary infection, **Lancet 344:1671-73, (1994).**

- Mckewicz C.E.3, Blackbourn J., Levy J. CD8+ T cells suppress human immunodeficiency virus replication by inhibiting viral transcription. **Proc. Natl. Acad. Sci. 92:2308-12, (1995).**
- Martin E., Kamath A.T., Briscoe H. et al. The combination of plasmid interleukin-12 with a single DNA vaccine is a more effective than Mycobacterium bovis(BCG) in a protecting against sytemic M.avium infection. **Immunology 109 308-14, (2003).**
- Martin HL:, Richardson BA., Nyange Pm, Laureys L., Hillier SL., Chohan B., et al. Vaginal Lactobacilli, microfloral, and risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisition**. J. Infect Dis. 180: 1863-8, (1999).**
- Martinez E., Conget I., Lozano L. et al. Reversions of metabolic abnormalities after swtching from HIV-1 protease inhibitors to nevirapine. **AIDS 13:805-10 (1999)**
- Mascola JR. Cellular immunity elicited by HIV-1/SIV DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies. **J Virol 77(19):10348-56, (2003).**
- Mascola JR., Stiegler G., VanCott TC., et al. Protection of machaques against vaginal transmission of pathogenic HIV-1/SIV chimeric virus passive infusion of neutralizing antibodies. **Nat Med. 6: 207-10, (2000).**
- Mateos F., Fuertes A., Marcos M., et al. Primary HIV infection with oesophageal candidiasis and acute toxoplasmosis. **An Med Interna 1: 50-1, (1998).**
- Matsuo K.1 Et al. Establishment of a foreign antigen secretion antigen system in mycobacteria. **Infect Immun 58, 4049-54, (1990).**
- Mazzantini R.P., Miyaji E.N., Dias W.O., et al. Adjuvant activity of BCG expressing on the immune response induced by BCG expressing tetanus fragment c. **Vaccine 26(5-6):740-6, (2004).**
- McCarthy M. HIV vaccine fails in phase III trial. **The Lancet 361:755-56, (2003).**
- McFadden J. Recombination in mycobacteria. **Molecular Microbiology 21(2), 215-211 (1996)**
- Mckeating J.A., Gow J., Goudsmit J. et al. Characterization of HIV-1 neutralization escape mutants, **AIDS. 3(12):777-84, (1989).**
- McMichel A.J.1, Hanke T. HIV vaccines 1983-2003. **Nature Medicine 9; 7:874-80, (2003).**
- McMichael A.J.2. How HIV Fools the immune System. **MRC News 1-5, (1996).**
- McMichael A.J.3 T cell responses and viral escape. **Cell 93: 673-676, (1998).**
- McMichael A.J.4, Rowland-Jones S., Cellular immune responses to HIV. **Nature 410:980-87, (2001).**
- McMurray D.N. Recent advances in improved tuberculosis vaccines. **Indian J.Pediatr 67(2 suppl):S58-62, (2000).**
- Medrano L.1, Perez L., Thomson M., Najera R. Avances en el desarrollo de vacunas frente al SIDA (parte I), **Pub. Of. SEISIDA 8:520-525, (2002).**

- Medrano L.2, Perez L., Thomson M., Najera R. Avances en el desarrollo de vacunas frente al sida (parte II). **Pub. Of. SEISIDA 13:572-577, (2002).**
- Medzhitov R.,Janeway Jr. Innate immunity, **N.Engl. J. Med. 343:338-44, (2000).**
- Melancon-Kaplan J., Hunter S., Dong T. et al. Immunological significance of Mycobacterium leprae cell walls. **Proc Natl Acad Sci USA 85(6)1917-1921 (1998)**
- Mellors J.W., Rinaldo C.R., Gupta P. et al. Prognosis in HIV infection predicted by the quantity of virus in plasma. **Science 272: 1167-9 (1996)**
- Meylan P.R., Guatelli J.C., Munis J.R. et al. Mechanisms for the inhibition of HIV replication by interferons, alpha-beta and-gamma in primary human macrophages, **Virology 193(1):138-48, (1993).**
- Migueles S.A., Sabbaghian M.S. Shupert W.L., et al. HLA B*5701 is highly assoiatednwith restriction of virus replication in a subgroup of HIV-infected long term nonprogressor. **Proc Natl Acad Sci USA, 97:2709-14, (2000).**
- Mins C., Dockrell H.M., Goering R.V., Roitt I., Wakelin D., Zucherman M. Medical Microbiology, **MosbyThird Edition 264-73, (2004).**
- Miró J.M., Sued O., Plana M. et al. Advances in the diagnosis and treatment of acute human immunodeficiency virus type 1 (HIV-1) infection. **Enferm Infecc Microbiol 22(10):643-59, (2004).**
- Mo H., Stamatatos L., Ip J.E. et a.l Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgG1b12.off, **J Virol. 71(9):6869-748, (1997).**
- Moos A.R.1, Hahn J.A., Perry S., et al. Adherence o highly active antirretroviral therapy in the homeless population in San Francisco: a prospecty study. **Clin Infect Dis 15;39(8):1190-8,(2004).**
- Moos P.J., Read R.C., Kudesia G., et al. Cryptosporidiasisnduring primary HIV infection. **J Infect 30: 51-3, (1995).**
- Msuya SE., Mbizvo E., Stray-Pedersen B., Sam Ne., Hussain A. Reproductive trac infections and the risk of HIV aming women in Moshi, Tanzania. **Acta Obstet Gynecol scand; 81:886-93,(2002).**
- Murray P.J., Aldovini A., Young R.A. Manipulation and potentiation of antimycobacterial immunity using recombinant bacille Calmette-Guérin strains that secrete cytokines. **Proc Natl Acad sci USA 93:934-9,(1996)**
- Mwau M, McMichel A. A review of vaccines for HIV prevention. **J Gene Med 5:3-10, (2003).**
- NIH www.niad.nih.gov /daids/vaccine/
- Nishimura Y., Igarashi T., Haigwood NL., et al. transfer of neutralizing IgG to macaques 6 h but 24 h after DHIV infection confers sterilizing protection: implications for HIV-1 vaccine development. **Proc Natl Acad Sci USA 100:15131-6, (2003).**
- Ogg G., Jin X., Bonhoeffer S. et al. Quantification of HIV-1-specific T lymphocites and plasma load of viral RNA. **Science 279(5359):2103-06 1998**
- On World AIDS Vaccine Day: 18th May, 2004. Progress and challenges. **IAVI report, May 17 th, (2004).** Ortiz G.M., Nixon D.F., Trkola A., et al.

HIV-1 specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly antiretroviral therapy. **J Clin Invest. 104:R13-8, (1999).**

- Ortiz G.M., Nixon D.F., Trkola A., et al. HIV-1 specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly antiretroviral therapy. **J Clin Invest. 104:R13-8, (1999).**
- Pal R., Venzon D., Letvin N. et al. ALVAC-SIV-gag-pol-env-base vaccination and macaque mayor histocompatibility complex class I(A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency. **J.Virol 76 292-302, (2002).**
- Palella F.J.1, Delaney K.M., Moorman A.C. et al. Declining morbidity and mortality among patients with advances human immunodeficiency virus infection. **N. Engl J. Med 338:853-60, (1998).**
- Palella F.J.2, Deloria-Knoll M., Chmiel J. et al. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. **Ann Intern Med. 138:620-26**.
- Pantaleo G., Graziosi C., Fauci A.S. The role of lymphoided organs in the pathogénesis of HIV infection, **Semin. Immunol. 5:157-63, (1993).**
- Parren P.W.1, Poignard P., Ditzel H.J. Antibodies in human infectious disease, **Immunol Res 21(2-3):265-78, (2000).**
- Parren P.W. 2, Moore J.P., Burton D.R., et al. The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity. **AIDS, 13 Suppl A: S137-62.**
- Pasare C., Medzhitov R. Toll-like receptors and acquired immunity.
- Pastinen T., Litsola K., Niini P., Salminen M., Syvanen A.C. Contribution of the CCR5 and MBL genes to susceptibility to HIV type-I infection in the finnish population, **AIDS Res. Hum. Retrovir, 14:695-98, (1998).**
- Pena J.M., Martínez M.A., Arnalich F., et al. Oesophageal candidiasis associated with acute infection due to human immunodeficiency virus**:** Case report and review. **Rev Infec Dis 13: 872-5, (1991).**
- Perelson A.S.1, Neumann A.U., Markowitz M. et al HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span and viral generation time. **Science 271:1582-86, (1996).**
- Perelson A.S.2, Essunger P., Cao Y. Decay characteristic of HIV-1 infected compartaments during combination therapy. **Nature 387:188-91, (1997).**
- Perri S., Greer C.E., Thudium K. et al. An alphavirus replicon particle chimera derived from Venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delibery vector. **J Virol. 77(19):10394-403, (2003).**
- Perrin L., Telenti A., HIV treatment failure: testing for HIV resistance in clinical practice. **Science 280(5371):1871-73, (1998).**
- Pett S.L.2 , Kellerher A.D. Cytokine therapies in HIV-1 infection: present and future. Expert Rev **Anti Infect Ther. 1(1):83-96, (2003).**
- Phimister E. In search of better HIV vaccine-the heat is on, **N Engl J M 348(7):643-44, (2003).**
- Piatak M. et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. **Science 259: 1749-54, (1993).**

- Pilcher C.D., Eron J.J., Galvin S., et al Acute HIV revised : new opportunities for treatmentand prevention. **J.Clin Invest 113: 937-45 (2004)**
- Pincus S.H., Messer K.G., Cole R. et al. Vaccine-specific antibody responses induced by HIV-1 envelope subunit vaccines, **J immunol. 1;158(7):3511-208, (1997).**
- Plana M., Garcia F., Gallart T., et al. Lack of T-cell proliferative response to HIV-1 antigens after one year of highly active antiretroviral therapy in early HIV-1 disease. **Lancet 352: 1194-95 (1998)**
- Podzamczer D., Ferrer E., Consiglio et al. A randomizwd trial comparing nelfinavir or nevirapine associated to ZDV/3TC in HIV-infected naïve patients (The combine study). **Antiviral Therapy 7:81-90 (2002)**
- Pomerantz R.J. 1. HIV-1 reservoirs. **Clin Lab Med. 22(3):651-80, (2002).**
- Pomerantz R.J.2, Horn D.L. Twenty years of therapy for HIV-1 infection. **Nat Med 9(7):867-73, (2003).**
- Pomerantz R.J.3, reservorious of human immunodeficiency virus type 1: the main obstacles to viral eradication. **Clin Infect Dis. 34:91-7, (2002).**
- Poppe M., Haase A.T. Transmission acute HIV-1 infection and the quest for strategies to prevent infection. **Nature Medicine Vol 9 (7):847-52, (2003).**
- Puppo F., Brenci S., Bosco O. et al. Downregulation of HLA class I antigen expression in CD4+ T lymphocytes from HIV type 1-infected individuals, **AIDS Res Hum retroviruses 20;13(17):1509-16, (1997).**
- Ortiz G.M., Nixon D.F., Trkola A., et al. HIV-1 specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly antiretroviral therapy. **J Clin Invest. 104:R13-8, (1999).**
- Rao A et al. A new generation of HIV Vaccines**. Trends in Molecular Medicine 8, 10:489-495, (2002).**
- Richman D.D., Wrin T., Little SJ., et al. Rapid evolution of the neutralizing antibody response to HIV-1 infection. **Proc Natl Acad Sci USA 1,100(7):4144-49, (2003)**.
- Romanus V., Svensson A., Hallander H.O. The impact of changing BCG coverage on tuberculosis incidence in Swedish Born children between 1969-and 1989. **Tuber Long Dis 73:150-61, (1992).**
- Rowland-Jones S.L.1, Dong T., Fowke K.R. et al. Cytotoxic T cells responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi, **J Clin Invest. 1,102(9):1758-65, (1998).**
- Rowland-Jones S.L.2, Sutton J., Ariyoshi K. et al, HIV specific cytotoxic T cells in HIV –exposed but uninfected Gambian women. **Nat Med 1(6):598, (1995)** .
- Rubinstein A., Mizrachi Y., Pettoello-Mantovani M., et al. Immunologic responses of Hiv-1-infected study subjects to immunization with a mixture of peptide protein derivative-V3 loop peptide conjugates. **J.Acquir Immune Defic Syndr 22(5):467-76 (1999).**
- Saifuddin M., Hart M.L., Gewurz H., Zhang Y.,Spear G. Interaction of manose-binding lectin with primary isolates of human immunodeficiency virus type I, **J. Gen. Virol. 81:949-55, (2000).**

- Samson M., Libert F., Doranz B.J., Rucker J., Liersnad C., Farber C.M., et al. Resistance to HIV-1 infection in caucausian individuals bearing mutant alleles of de CCR5 chemokine receptor gene, **Nature 382:722-25, (1996).**
- Schacker T.1, Collier A.C., Hugghes J. et al.Clinical and epidemiologic features of primary HIV infection, **Ann Intern Med 125:257-64, (1996).**
- Schacker T.2, Hugghes J., Shea T., et al. Biological and virologic characteristics of primary HIV infection. **Ann Intern Med 128:613-20, (1998).**
- Shiver J.W. Comparative studies of several HIV vaccines approaches. AIDS vaccines in the new milleniun. **Keystone Symposia**
- Schmitz J. et al. Effect of Humoral Immune Responses on Conrolling Viremia during Primary Infection of Rhesus Monkeys with Simian Immunodeficiency Virus**. Jour of Vir 77:2165-2173, (2003).**
- Siegal F.P.1, Spear G.T. Innate immunity and HIV,**AIDS 15:127-137, (2001).**
- Siegal F.P.2, Lopez C., Firzgerald P.A., Shah K., Baron P., Leiderman I.Z., et al. Opportunistic infections in acquired immune deficiency syndrome result from synergistic defects of both the natural and adaptative components of celular immunity, **J. Clin Invest. 78:115-23, (1986).**
- Siegal F.P.3, Kadowaki N., Shodell M., Firzgerald-Bocarsly P.A., Shah K., Ho S. et al. The nature of the principal type I interferon producing cell in human blood, **Science 284:1835-37, (1999).**
- Smith K. The HIV vaccine saga. **Medical Immunology 2:,1-7, (2003).**
- Soumelis V.1, Scott I., Gheyas F. et al. Depletion of circulating natural type 1 interferon-producing cells in HIV-infected AIDS patients. **Blood. 98(4):906-12, (2001).**
- Soumelis V.2 , Scott I, Liu Y.J. et al. Natural Type 1 interferon producing cells in HIV infection. **Hum Immunol 63(12):1206-12 ,(2002)** .
- Spear G.T. Interaction of non-antibody factors with HIV in plasma, **AIDS 7 1149-57(1993)**
- Staszewski S., Morales R. J., Tashima K.T. et al. Efavirenz plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. **N. Engl Med 341: 1865-73 (1999)**
- Sterne J.A.C., Rodriguez L.C., Guedes I.N. Does the efficacy of BCG decline with time since vaccination?. **Int J Tuberc Lung Dis 2,200-7(1998)**
- Stevenson M. HIV-1 **p**athogenesis**. Nature Med 9:853-60, (2003).**
- Stiehm E.R., Fletcher C.V., Mofenson L.M. et al. Use of human immunodeficiency virus (HIV) human hiperimmune immunoglobulin in HIV type-infected children, **Infect Dis. 181(2): 548-54**
- Stover C.K 1., de la Cruz V.F., Fuerst T.R., et al. New use of BCG for recombinant vaccines. **Nature 351:456-60,(1991).**
- Stover C K 2, Bansal GP, Hanson MS, Burlein JE, Palaszynski SR, Young JF, Koenig S, Young DB, Sadziene A, Barbour AG. Protective immunity elicited by recombinant bacille Calmette-Guerin (BCG)

expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine. **J Exp Med 178(1):197-209,(1993).**

- Stranford S., Skurmick J., Louria D., Osmond D., Chang S., Snisky J. Lack of infection in HIV-exposed individuals is associated with a strong CD8+ cell noncytotoxic anti-HIV response, **Proc Natl. Acad. Sci 96:1030-35, (1999).**
- Sullivan B.L., Knopoff E.J., Saifuddin M., et al. Susceptibility of HIV plasma virus to complement-mediated lysis, **J. Immunol. 157:1791-98, (1996).**
- Szabo S., James C.W., Telford G. Unusual presentations of primary human inmmunodeficiency virus infections. **AIDS Patient Care STDS 16:251-4, (2002).**
- Thaitawat N., Nacapew S., Chaiwong V., et al. Collaborating with NGOs and community groups to raise AIDS awareness and to go engage the community to participative in the prime-boost vaccine phase trial in Chon Buri and Rayond provinces, eastern Thailand. **XV International AIDS Conference, Bangkok (Thailand) abstract C7448, (2004**).
- Tindall B.1, Cooper D.A., Primary HIV infection: host responses and intervention strategies, **AIDS 5:1-14, (1997).**
- Tindall B.1, Cooper D.A., et al. Primary human immunodeficiency virus infection. Clinical and serologyc aspect. **Infect Dis Clin North Am 2:329-41, (1988).**
- Tramont E., Johnston M.I., Progress in the development of an HIV vaccine. **Expert Opin. Emerging Drugs 8:37-45,(2003).**
- Trivuthipong C. Thailand's prime –boost HIV vaccine trial (Letter). **Science 303:Issue 5660; 954-955, (2004).**
- Turpin J.A. The next generation of HIV/AIDS drugs: novel and developmental antiHIV drugs and targets. **Expert Rev Anti Infect Ther. (1):97-128, (2003)**.
- UNAIDS. **Report on the Global HIV/AIDS** Epidemic<http://www.unaids.org/epidemic_update/report_july02/index.html (**UNAIDS, Geneva, 2002**).
- UNAIDS, AIDS epidemic update: Geneva: **UNAIDS 2004**
- Vajdy M., Gardner J., Neidleman J. et al. Human immunodeficiency virus type 1 gag-specific vaginal immunity and protection after local immunization with sindbis virus-based replicon particles. **J Infect Dis. 184(12):1613-6, (2001).**
- Vanhems P.1, Dassa C., Lambert J., et al. Comprehensive classification of symptoms and sings reporter among 218 patients with acute HIV-1 infection. **J Acquir Immune Defic Syn 21:99-106,(1999).**
- Vanhems P.2, Voiring N., Hirschel B., et al. Brief report: Incubation and duration of specific sympthoms acute retroviral syndrome as independt predictors of progression to AIDS. **J Acquir Immune Defic Syndr 32:542-4, (2003).**
- Vanhems P.3, Hirschel B., Philips A.N. et al. Incubation time of acute human immunodeficiency virus (HIV) infection and duration of acute HIV infection are independent prognostic factors of progression to AIDS. **J infect Dis 182:334-7, (2002).**

- Varaldo P.B., Leite L.C., Dias W.O., et al. Recombinant Mycobacterium bovis BCG expressing the Sm1 antigen of *Schistosoma mansoni* protects mice from cercarial challenge. **Infect Immun. 72(6):3336-43, (2004).**
- Vento S., Di Perry G., Garonfano T.,et al. *Pneumocystis carinii* Pneumonia during primary HIV-1 infection. **Lancet 342:24-5, (1993).**
- Vittecoq D., Chevret S., Monrad-Joubart L., et al. Passive immunotherapy in AIDS: a double-blind randomized study based on transfusion of plasma rich in anti-human inmunodficiency virus 1 antibodies vs. transfusions of seronegative plasma. **Proc Natl Acad Sci USA. 92:1195-9, (**1995.).
- Wada N., Ohara N., Kameoka M, Nishino Y., Matsumoto S, Nishiyama T, Naito M, Yukitake H, Okada Y, Ikuta K, Yamada. T.Long-lasting immune response induced by recombinant bacillus Calmette-Guerin (BCG) secretion system. **Scand J Immunol 43(2):202-9, (1996).**
- Walensky R.P., Rosenberg E.S., Ferraro J.M., et al. Investigation of primary human immunodeficiency virus infection in patients for heterophile antibody. **Clin Infec Dis 33:570-2, (2001).**
- Walker B.D., Korber B.T. Immune control of HIV: the obstacles of HLA and viral diversity. **Nat. Immunology 2(6): 473-75, (2001).**
- Walsh S.R., Bhardwaj N. Gandhil R.T. Dentritic cells and the promise of therapeutic vaccines for human immunodeficiency virus (HIV-1). **Curr HIV Res. 1(2):205-16, (2003).**
- Weidle P.J., Mastro T.D., Grant A.D., et al HIV / AIDS treatment and HIV vaccines for Africa. **The Lancet 539:2261-67, (2002).**
- Williams N.S., Engelhard V.H. Perforin-dependent cytotoxic activity and lymphokine secretion by CD4+ T cells are regulated by CD8+ T cells. **J immunol. 1;159(5):2091-9, (1997).**
- Winter N 1, Lagranderie M, Rauzier J, Timm J, Leclerc C, Guy B, Kieny MP, Gheorghiu M, Gicquel B. Expression of heterologous genes in Mycobacterium bovis BCG: induction of a cellular response against HIV-1 Nef protein. **Gene 20;109(1):47-54, (1991).**
- Winter N 2, Lagranderie M, Gangloff S, Leclerc C, Gheorghiu M, Gicquel B. Recombinant BCG strains expressing the SIVmac251nef gene induce proliferative and CTL responses against nef synthetic peptides in mice. **Vaccine (5):471-8, (1995).**
- Wodarz D., Jansen V.A. The role of the cell help for anti-viral CTL responses. **J Theor Biol. 21;211(4):419-32, (2001).**
- Weidle P.J., Mastro T.D., Grant A.D., et al. HIV/AIDS treatment and HIV vaccines for Africa. **The Lancet 359(9325):2261-67, (2002).**
- Wong K.H., Chan K.C., Lee S.S. Delayed progression to death and to AIDS in a Hong Kong Of patients with advanced HIV-1 disease during the era of highly active antiretroviral therapy. **Clin Infect Dis 15;39(6):853-60, (2004).**
- World Health Organization. State of the world's vaccines and Immunization. **W.H.O., Unicef T.W.B, (2003).**

- Wong J.K., Hezareh M., Gunthard H.F., et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. **Science; 278:1291-5, (1997).**
- Xu L., Du X., Zhang W., et al. DNA shuffling creats HIV-1 variants that induce broadly neutralizing antibodies in rabbits. (abstrac 95) **AIDS Vaccine Lausanne, (2004).**
- Yasutomi Y 1, Koenig S, Haun SS, Stover CK, Jackson RK, Conard P, Conley AJ, Emini EA, Fuerst TR, Letvin NL. Immunization with recombinant BCG-SIV elicits SIV-specific cytotoxic T lymphocytes in rhesus monkeys. **J Immunol 1;150(7):3101-7, (1993).**
- Yasutomi Y 2, Koenig S, Woods RM, Madsen J, Wassef NM, Alving CR, Klein HJ, Nolan TE, Boots LJ, Kessler JA, et al. A vaccine-elicited, single viral epitope-specific cytotoxic T lymphocyte response does not protect against intravenous, cell-free simian immunodeficiency virus challenge. **J Virol 69(4):2279-84, (1995).**
- Yen C.F., Tsai J.J., Lu P.I., et al Quality of life and its correlates in HIV/AIDS male outpatientes receiving highly active antiretroviral therapy in Taiwan. **Psychiatry Clin Neurosci 58(5):501-6, (2004).**
- Yeni P.G., Hammer S.M., Hirsch M.S. et al. Treatment for adult HIV infection : 2004 recommendations of the International AIDS Society-USA Panel. **JAMA 14;292(“):251-65 (2004)**
- Yu D.S., Lee C.f., Hsieh D.S. et al. Antitumor effects of recombinant BCG and interleukin-12 D vaccines on xenografted murine bladder cancer. **Urology 63(3):596-601, (2004).**
- Zheng C., Xie P., Chen Y. Molecular cloning and secuencing of merozoite surface a gene from Plasmodium falciparum strain FCC-1/HN and expressing of the gene in mycobacteria. **Eukaryot Microbiol. 50(2):140-3, (2003).**
- Ziv E., Daley CH. L., Blower S. Potential public health impact of new tuberculosis vaccines. **Emerging Infectious Diseases 10(9):1529-1533, (2004).**
- Zhang L., Yu W., Tian H. et al. Contribution of human alpha-defensinas 1, 2 y 3 to the anti-HIV-1 activity of CD8 antiviral factor. **Science 298:995-1000,(2002).**
- Zhang Z., Schuler T., zupancic M., Wietgrefe S., Staskus KA., Reimann KA., et al. Secual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. **Science, 286:1353-7,(1999).**
- Zhang L., Ramratnam B., Tenner-Racz K. et al. Quantififying residual HIV-1 replication in patients receiving combination antiretroviral therapy. **N Engl Med 340: 1605-13 (1999)**